| Literature DB >> 29335397 |
Rupesh Raina1, Joseph Wang2, Vinod Krishnappa3, Maria Ferris4.
Abstract
The transition from pediatric to adult medical services is an important time in the life of an adolescent or young adult with a renal transplant. Failure of proper transition can lead to medical non-adherence and subsequent loss of graft and/or return to dialysis. The aim of this study was to conduct a systematic review and survey to assess the challenges and existing practices in transition of renal transplant recipient children to adult services, and to develop a transition protocol. We conducted a literature review and performed a survey of pediatric nephrologists across the United States to examine the current state of transition care. A structured transition protocol was developed based on these results. Our literature review revealed that a transition program has a positive impact on decline in renal function and acute rejection episodes, and may improve long-term graft outcomes in pediatric kidney transplant patients. With a response rate of 40% (60/150) from nephrologists in 56% (49/87) of centers, our survey shows inconsistent use of validated tools despite their availability, inefficient communication between teams, and lack of use of dedicated clinics. To address these issues, we developed the "RISE to Transition" protocol, which relies on 4 competency areas: Recognition, Insight, Self-reliance, and Establishment of healthy habits. The transition program decreases acute graft rejection episodes, and the main challenges in transition care are the communication gap between health care providers and inconsistent use of transition tools. Our RISE to transition protocol incorporates transition tools, defines personnel, and aims to improve communication between teams.Entities:
Mesh:
Year: 2018 PMID: 29335397 PMCID: PMC6248065 DOI: 10.12659/aot.906279
Source DB: PubMed Journal: Ann Transplant ISSN: 1425-9524 Impact factor: 1.530
Transplant transition survey questionnaire and responses.
| Question | Total responses | Yes | No |
|---|---|---|---|
| 1. Is there a transition clinic for transplant patients in place at your hospital? | 60 | 14 (23%) | 46 |
|
| |||
| 2. Is there an up-to-date health summary (Passport) composed for each patient? | 60 | 22 (37%) | 38 |
|
| |||
| 3. Is there a written health care transition plan for each patient and their family? | 60 | 20 (33%) | 40 |
|
| |||
| 4. Did you complete a checklist of critical tasks and milestones to achieve throughout childhood and adolescence prior to transfer? | 59 | 23 (39%) | 36 |
|
| |||
| 5. Was the patient prepared for his/her responsibilities in regard to health care, education, financial and social responsibilities as he/she matures? | 59 | 36 (61%) | 23 |
|
| |||
| 6. Was there collaboration between adult transplant team regarding their expectations, clinic set-up and clinic protocols? | 60 | 33 (55%) | 27 |
|
| |||
| 7. Was there an effective partnership with the pediatric team for bidirectional information exchange in the following areas? | 56 | 32 (57%) | 24 |
| Practices | 56 | 27 (48%) | 29 |
| Protocols | 56 | 31 (55%) | 25 |
| Treatment Plans | |||
|
| |||
| 8. Was there a standardized assessment of readiness for care conducted? | 46 | 14 (30%) | 32 |
|
| |||
| 9. Do you utilize transplant transitional care questionnaires to help guide this process? | 48 | 11 (23%) | 37 |
|
| |||
| 10. Is there involvement of adult transplant physicians involved at least 1 year prior to transition? | 60 | 15 (25%) | 45 |
|
| |||
| 11. Is there a designated transplant transition coordinator? | 60 | 15 (25%) | 45 |
|
| |||
| 12. Was there effective communication and education on behalf of the primary care provider regarding care beyond the norm for the young adult ESRD patient? | 60 | 18 (30%) | 42 |
|
| |||
| 13. Do you have a reproductive specialist and urologist proficient in congenital urologic malformations? | 60 | 48 (80%) | 12 |
|
| |||
| 14. What personnel are utilized during the transition of care process? | 49 | n/a | n/a |
| Pediatric nephrologist | 40 | ||
| Adult nephrologist | 34 | ||
| Social worker | 27 | ||
| Transition coordinator | 10 | ||
| Nursing | 16 | ||
| Transplant coordinator | 4 | ||
| Dietician | 5 | ||
| Psychology | 6 | ||
| Nurse practitioners | 3 | ||
| Teachers | 1 | ||
| Pharmacy | 1 | ||
| Med-peds nephrologist | 1 | ||
| Young health workers | 1 | ||
| Adult Transplant surgeon | 1 | ||
| Child Life | 1 | ||
| Primary care physician | 1 | ||
|
| |||
| 15. How many transplant patient transitions do you complete each year? | 59 | n/a | n/a |
| 0–5 | 47 | ||
| 5–10 | 9 | ||
| 10–15 | 3 | ||
| >15 | 0 | ||
|
| |||
| 16. At what age does the patient begin the transition process? | 59 | n/a | n/a |
| 8–10 years | 1 | ||
| 10–12 years | 4 | ||
| 12–14 years | 11 | ||
| 14–16 years | 14 | ||
| 16–18 years | 29 | ||
|
| |||
| 17. Is the transition process complete at the time of transfer to adult-focused services? | 59 | 35 (59%) | 24 |
Figure 1Flow diagram of survey distribution and responses received.
Figure 2Screening flow chart.
Studies on transition care in pediatric renal transplant patients.
| Study/Year | No. of patients | Tools/intervention used | Outcomes | Conclusion/recommendations |
|---|---|---|---|---|
| Weitz et al. [ | 59 | Transition programs | Fall in eGFR was significantly low at 3 yrs after transition despite age of graft in TP group was almost twice the age of graft in control group. Also, decreased number of AR’s in TP group compared to control group although it was not statistically significant | Standardized multilevel TP has a positive impact on decline in renal function and AR episodes in pediatric kidney transplant patients |
| McQuillan et al. [ | 32 | Kidney transplant transfer clinic | Improved adherence & renal function | May improve long-term graft outcomes in transplant recipients |
| Marchak et al. [ | 49 | Readiness for Transition Questionnaire – Provider (RTQ-Provider), RTQ-Teen & RTQ-Parent | RTQ has ability to strengthen interpersonal communication among patients, families and healthcare providers to assess and recognize factors that affect transition readiness. | Future research is required to demonstrate predictive validity of this intervention post transition to adult care |
| Kreuzer [ | 119 | Standardized questionnaire to assess present transition care practices in Germany & Austria | Transition care varies significantly between centers despite existence of highly specialized care. Significant rise in serum creatinine levels noted in 21% of patients during last visit to pediatric clinic. Majority of patients demonstrated coefficient of variation for immunosuppressive medication trough levels <20% which was indicative of good medication compliance evidenced by reduced rates of transplant rejection (coefficient of variation for tacrolimus trough levels <40% not found to be associated with increase in risk of transplant rejection) | Recommended for improvement in transition and psychosocial care including patient education. Phase 2 of the study, a prospective randomized control trial is ongoing which is aimed at providing a model of structured transition |
| Akchurin [ | 97 | Tacrolimus trough levels and its variability used to assess differences in medication compliance before and after transition, and between transitioned and control groups | No statistically significant difference in medication compliance was found in the transitioned group before and after transition, and between transitioned group and young adult control group who had renal transplantation under adult care. However, medication non compliance rate was found to be higher in non-transitioned adolescent control group who had graft loss when they were still under pediatric care compared to transitioned group | Medication compliance was not related to transition from pediatric to adult care in the same center, but adolescent age was shown to be risk factor for non-compliance. However larger prospective trials required to demonstrate this relationship |
| Pape et al. [ | 66 | Specialized transition clinic | Patients transferred to transition clinic showed high level of satisfaction and small number of medication regimen changes compared to the other two groups transferred to nephrologists in private practice and general transplantation clinic. However, there were no significant differences in renal function decline among three groups in short-term | Transfer to specialized clinic was not associated with short-term benefits in terms of graft function and survival |
| Andreoni et al. [ | 168,809 | NA | Patients between 14 and 16 years of age, found to have high risk of graft loss with black adolescents having worst outcome. Further, patients who had deceased donor and government insurance were found to have highest risk of death compared to those with living donor and private insurance. | Adolescents between 14 to 16 years of age are at higher risk of renal transplant failure with highest risk observed among black population and patients with government insurance |
| Van Den Heuvel et al. [ | 162 | NA | Acute graft rejection episodes were significantly higher before transition. The risk of graft rejections reduced after transition to adult care and this reduction was more pronounced in native Dutch patients compared to immigrants | Acute graft rejection risk reduces after transition to adult care |
| Koshy et al. [ | 115 | NA | There was no increase in risk for renal allograft failure during transition. Furthermore, hospitalizations for graft rejection or biopsy were found to be lower after 18 years of age. | Transition to adult care does not increase the risk of allograft failure |
| Chaturvedi et al. [ | 11 | Transition questionnaire was used to demonstrate level of satisfaction and transition process perception in patients who were transitioned through transition clinic. | This study demonstrated that adolescents participation in transition planning and preparation before transfer to adult care were insufficient | Adolescents should be involved actively in transition planning from the beginning |
Milestone checklist.
|
Understanding of and ability to describe the original cause of their organ failure, need for transplantation – Use passport and My precious life gift handout; repetition is necessary to ensure they understand their condition Awareness of the long and short-term implications of the transplant condition on their overall health and other aspects of their life (e.g. infection prevention, cancer surveillance, academic and vocational aspirations) Comprehension of the impact of their illness on their sexuality and reproductive health, including – The impact of pregnancy on their own wellbeing – The effect of their medications on fertility any potential teratogenicity of their medications – The role of genetic counseling, and genetic risk of their disease recurrence in future offspring, if pertinent to their condition – Their own increased susceptibility for sexually transmitted disease Demonstration of a sense of responsibility for their own healthcare – Knowledge of the names, (and shapes/colors), indications and dosages of their transplant and ancillary medications (or carry this information in wallet/purse) – Call for their own prescription refills and renewals – Prepare their own medication dose boxes, if not done by their pharmacist – Independently communicate their health care needs to their providers – Teach them when and how to seek urgent medical attention, including health emergency telephone number(s) – Ability to make, keep a calendar of and follow through with their own health care appointments – Understanding of their medical insurance coverage and eligibility requirements Capacity to provide most self-care independently An expressed readiness to move into adulthood Ownership of their medical information in a concise portable accessible summary Make them CEO of their own health problem. |
Figure 3Transition flow diagram.
Pre-transition stage: age 14–18.
|
During this phase, the pediatric transplant team will begin laying the groundwork for transition Begin searching for adult PCP with help of family Emphasis on Understand their disease Understand reason for transplant Emphasis on Begin understanding risk of non-adherence Being understanding the long-term health effects Laying the groundwork for Medication regiment becomes a routine Begin understanding urgent/emergent changes in their health More involvement at appointments Encourage the patient to ask questions on how to prepare for transition Begin Healthy choices Emphasis on adherence to treatments Emphasis on vocational and educational future In order to assist with the transition, a checklist of milestones will be provided to the pediatric transplant team |
Check list of tasks for pediatric transplant team.
|
Demographics Transplant date and organ H&P summary Last clinic note and lab work Medication list Problem list Pharmacy and lab numbers PCP Insurance status Present to the Transition Committee Date anticipated for transfer Review the process with patient/family – Verbally – Letter Confirm the patient is able to make the transition successfully Present to adult transition team – Specific template – Adult and pediatric participants – Multidisciplinary group: surgeon/doctor, nurses (NPs), social work – Financial counselor – Discussion and recommendations Schedule a combined adult – pediatric clinic Written health care transition plan should be created together with the patient and family Milestones to achieve prior to transfer are described Standardized transition preparedness questionnaire for an assessment of transition readiness Communicate to adult providers at transfer and incorporate areas in need of attention, including individualized information about methods most successfully used to optimize immunosuppressive medication adherence Patients should be provided with a portable concise, up-to-date summary of their medical/surgical history and medications (Medical Passport) |
Active transition stage: age 18–21.
|
Transition will be initiated by the Pediatric transplant team Written transition plan to be provided by pediatric team Adult PCP should be fully established with effective bi-directional communication Establish contact with adult transplant team Provide patient with a medical passport Continue with education of RISE competencies Baseline assessment of RISE competencies Based on the results, education will be tailored for weaknesses Use of standardized readiness assessments (STARx, TRxANSITION) After baseline assessment, these will be used to monitor progress Readiness will be reassessed every 6 months Facilitate combined pediatric and adult clinic visits Coordinate use of transition tools: Passport, milestone checklists Passport use will be examined 3 and 6 months into transition (Medical passport survey) Educate patient on expectations of adult clinic Reinforce disease and treatment knowledge Assist in knowledge acquisition of insurance and other non-clinical aspects of health care Reinforce long term outcomes for their disease Reinforce long term consequences of non-adherence Educate patient on skills such as making appointments, refills, and other clinic related skills Reinforce prior education on identifying urgent/emergent changes to their health 1. Reinforce healthy habits established in pediatric care 1. Continue to promote gaining healthy habits Adult transplant team will have a milestone checklist to complete |
Checklist of tasks for adult transplant team.
|
Welcoming and orienting the new young adult into the adult practice Following review of the transfer package, the initial appointment should address any concerns that the young adult may have in transferring to a new adult provider and distinctions between pediatric and adult care To discuss confidentiality, access to information, and shared decision-making and to elicit how to best communicate with the young adult Over the next few visits, the provider should work with the young adult to assess and strengthen self-care skills Providers can use the results of this assessment to develop a plan of care with the young adults The adult practice must communicate with the pediatric practice about their residual responsibility for care until the first visit to the adult provider is completed (e.g. medication refills or acute care visits) In the case of young adults with complicated health or psychosocial needs, direct provider communication is encouraged Adult providers can also establish a plan for further consultation with the pediatric provider should the need arise Community resource information on insurance, self-care management, and culturally appropriate supports can be helpful to young adults |
Post-transition stage: age 21–26.
|
Transition will be completed by age 21 Assume care of patient as primary team Continue to encourage maintenance of RISE competencies Will remain on as ancillary support for the adult team Will remain with patient as support Will hand over health care responsibilities to patient 6-month post transition assessment Appointment adherence Percentage missed will be measured and recorded Reason for missing appointments will be recorded Overt (willful) Covert (Forgetfulness or denial) Socio-economic (transport, finances, work-related, etc.) Medication adherence Assessment by: i. Self-report i. Pharmacy refill information (Non-adherence=adherent <75% of time) Continue to monitor long term outcomes Transition provider survey for treatment, lab and adherence information at baseline, 6, 12 and 24 months Patient satisfaction survey at baseline and every 6 months Parent survey on transition at baseline and every 6 months Quality outcome assessment after 3 consecutive adult appointments Ongoing evaluation at 1, 2, 3, and 5 years |
PRISMA 2009 checklist.
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Page No. | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both | 4 |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number | 2, 3 |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known | 3, 4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS) | 4 |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number | No |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale | 5 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched | 5 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated | 5 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | 5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators | 5 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis | |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means) | NA |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis | NA |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies) | |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified | NA |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram | 6 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations | |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12) | |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot | |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency | NA |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15) | |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]) | NA |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers) | 5, 6 & |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias) | |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research | 5, 6 |
| 5, 6 | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review | 24 |
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 2009; 6(7): e1000097. For more information, visit: .